Phosphodiesterase 7 (PDE7) as a therapeutic target

Drugs of the Future

Volumn 31, Issue 3, 2006, Pages 207-229

  Giembycz, Mark A ^a   Smith, Susan J ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [6,7 DIETHOXY 2,3 BIS(HYDROXYMETHYL) 1 NAPHTHYL] 2 PYRIDYL] 4 (3 PYRIDYL) 1(2H) PHTHALAZINONE; 2 FLUOROBENZOIC ACID DERIVATIVE; 2 METHYL 5 NITROBENZENESULFONIC ACID DIMETHYLAMIDE; 4 AMINO 2 METHYLQUINAZOLINE DERIVATIVE; BENZENESULFONAMIDE DERIVATIVE; BENZENESULFONANILIDE DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; BENZOTHIENOTHIADIAZINE DERIVATIVE; BMS 586353; DIHYDROISOQUINOLINE DERIVATIVE; DIHYDROISOXAZOLE DERIVATIVE; IMIDAZOLE DERIVATIVE; IMIDAZOTRIAZINONE DERIVATIVE; PHOSPHODIESTERASE; PHOSPHODIESTERASE II INHIBITOR; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; PHOSPHODIESTERASE VII; PICLAMILAST; PURINE NUCLEOTIDE; PYRAZOLOPYRIMIDINONE DERIVATIVE; PYRIMIDINE NUCLEOTIDE; PYRROLE DERIVATIVE; QUINAZOLINONE DERIVATIVE; SPIROQUINAZOLINONE DERIVATIVE; SULFONAMIDE; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SEQUENCE; ASTHMA; ATOPIC DERMATITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CROHN DISEASE; DIABETES MELLITUS; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYMOLOGY; GENE; GENE CONTROL; GENE EXPRESSION; GENE STRUCTURE; GENETIC VARIABILITY; HUMAN; IC 50; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; INFLAMMATORY CELL; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PHARMACOPHORE; PHOSPHODIESTERASE 7A GENE; PHOSPHODIESTERASE 7A1 GENE; PHOSPHODIESTERASE 7A2 GENE; PHOSPHODIESTERASE 7A3 GENE; PHOSPHODIESTERASE 7B GENE; PHOSPHODIESTERASE 7B1 GENE; PROMOTER REGION; PROTEIN EXPRESSION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TISSUE DISTRIBUTION; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

EID: 33646798806     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2006.031.03.966246     Document Type: Review

References (109)

1. Butcher, R.W., Sutherland, E.W. Adenosine 3′,5′-phosphate in biological materials. I. Purification and properties of cyclic 3′,5′-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3′,5′-phosphate in human urine. J Biol Chem 1962, 237: 1244-50.
2. Soderling, S.H., Bayuga, S.J., Beavo, J.A. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 1998, 273: 15553-8.
3. Beavo, J.A. Multiple isozymes of cyclic nucleotide phosphodiesterase. Adv Second Messenger Phosphoprotein Res 1988, 22: 1-38.
4. Beavo, J.A. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 1995, 75: 725-48.
5. Conti, M., Jin, S.L. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 1999, 63: 1-38.
6. Lugnier, C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol Ther 2005, 109: 366-98.
7. Liu, Y., Shakur, Y., Yoshitake, M., Kambayashi, J.J. Cilostazol (Pletal): A dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 2001, 19: 369-86.
8. Giembycz, M.A. Cilomilast: A second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Invest Drugs 2001, 10: 1361-79.
9. Baeumer, W., Szelenyi, I., Kietzmann, M. Cilomilast, an orally active phosphodiesterase 4 inhibitor for the treatment of COPD. Exp Opin Clin Immunol 2005, 1: 27-36.
10. Dyke, H.J., Montana, J.G. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Invest Drugs 2002, 11: 1-13.
11. Rotella, D.P. Phosphodiesterase 5 inhibitors: Current status and potential applications. Nat Rev Drug Discov 2002, 1: 674-82.
12. Galie, N., Ghofrani, H.A., Torbicki, A. et al. Sildenafil citrate therapy for pulmonary arterial hypertension. New Engl J Med 2005, 353: 2148-57.
13. Michaeli, T., Bloom, T.J., Martins, T. et al. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J Biol Chem 1993, 268: 12925-32.
14. Ichimura, M., Kase, H. A new cyclic nucleotide phosphodiesterase isozyme expressed in the T-lymphocyte cell lines. Biochem Biophys Res Commun 1993, 193: 985-90.
15. Bloom, T.J., Beavo, J.A. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc Natl Acad Sci USA 1996, 93: 14188-92.
16. Hetman, J.M., Soderling, S.H., Glavas, N.A., Beavo, J.A. Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. Proc Natl Acad Sci USA 2000, 97: 472-6.
17. Sasaki, T., Kotera, J., Yuasa, K., Omori, K. Identification of human PDE7B, a cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 2000, 271: 575-83.
18. Hoffmann, R., Abdel'Al, S., Engels, P. Differential distribution of rat PDE-7 mRNA in embryonic and adult rat brain. Cell Biochem Biophys 1998, 28: 103-13.
19. Sasaki, T., Kotera, J., Omori, K. Novel alternative splice variants of rat phosphodiesterase 78 showing unique tissue-specific expression and phosphorylation. Biochem J 2002, 361: 211-20.
20. Han, P., Fletcher, C.F., Copeland, N.G., Jenkins, N.A., Yaremko, L.M., Michaeli, T. Assignment of the mouse Pde7A gene to the proximal region of chromosome 3 and of the human PDE7A gene to chromosome 8q13. Genomics 1998, 48: 275-6.
21. Milatovich, A., Bolger, G., Michaeli, T., Francke, U. Chromosome localizations of genes for five cAMP-specific phosphodiesterases in man and mouse. Somat Cell Mol Genet 1994, 20: 75-86.
22. Minassian, B.A., Lee, J.R., Herbrick, J.A. et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet 1998, 20: 171-4.
23. + channels causes epilepsy. Nature 1998, 396: 687-90.
24. Torras-Llort, M., Azorin, F. Functional characterization of the human phosphodiesterase 7A1 promoter. Biochem J 2003, 373: 835-43.
25. Glavas, N.A., Ostenson, C., Schaefer, J.B., Vasta, V., Beavo, J.A. T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc Natl Acad Sci USA 2001, 98: 6319-24.
26. Han, P., Zhu, X., Michaeli, T. Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart. J Biol Chem 1997, 272: 16152-7.
27. Kasuya, J., Liang, S.J., Goko, H. et al. Cardiac type cGMP-inhibited phosphodiesterase (PDE3A) gene structure: Similarity and difference to adipocyte type PDE3B gene. Biochem Biophys Res Commun 2000, 268: 827-34.
28. Niiya, T., Osawa, H., Onuma, H. et al. Activation of mouse phosphodiesterase 3B gene promoter by adipocyte differentiation in 3T3-L1 cells. FEBS Lett 2001, 505: 136-40.
29. Rena, G., Begg, F., Ross, A. et al. Molecular cloning, genomic positioning, promoter identification, and characterization of the novel cyclic AMP-specific phosphodiesterase PDE4A10. Mol Pharmacol 2001, 59: 996-1011.
30. Olsen, A.E., Bolger, G.B. Physical mapping and promoter structure of the murine cAMP-specific phosphodiesterase PDE4A gene. Mamm Genome 2000, 11: 41-5.
31. Vicini, E., Conti, M. Characterization of an intronic promoter of a cyclic adenosine 3′,5′-monophosphate (cAMP)-specific phosphodiesterase gene that confers hormone and cAMP inducibility. Mol Endocrinol 1997, 11: 839-50.
32. Le Jeune, I.R., Shepherd, M., Van Heeke, G., Houslay, M.D., Hall, I.P. Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter. J Biol Chem 2002, 277: 35980-9.
33. Lin, C.S., Chow, S., Lau, A., Tu, R., Lue, T.F. Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters. Int J Impot Res 2002, 14: 15-24.
34. Lin, C.S., Chow, S., Lau, A., Tu, R., Lue, T.F. Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: Identification of a critical Sp1-binding site. Biochem Biophys Res Commun 2001, 280: 693-9.
35. Lin, C.S., Chow, S., Lau, A., Tu, R., Lue, T.F. Identification and regulation of human PDE5A gene promoter. Biochem Biophys Res Commun 2001, 280: 684-92.
36. Lin, C.S., Lau, A., Tu, R., Lue, T.F. Identification of three alternative first exons and an intronic promoter of human PDE5A gene. Biochem Biophys Res Commun 2000, 268: 596-602.
37. Taylor, R.E., Shows, K.H., Zhao, Y., Pittler, S.J. A PDE6A promoter fragment directs transcription predominantly in the photoreceptor. Biochem Biophys Res Commun 2001, 282: 543-7.
38. Seybold, J., Newton, R., Wright, L. et al. Induction of phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in Jurkat T-cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and Gs-coupled receptor agonists. Potential role in α2-adrenoreceptor desensitization. J Biol Chem 1998, 273: 20575-88.
39. Lee, R., Wolda, S., Moon, E., Esselstyn, J., Hertel, C., Lerner, A. PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP. Cell Signal 2002, 14: 277-84.
40. Graef, I.A., Chen, F., Crabtree, G.R. NFAT signaling in vertebrate development. Curr Opin Genet Dev 2001, 11: 505-12.
41. Macleod, K., Leprince, D., Stehelin, D. The ets gene family. Trends Biochem Sci 1992, 17: 251-6.
42. Kontny, E., Kurowska, M., Szczepanska, K., Maslinski, W. Rottlerin, a PKC isozyme-selective inhibitor, affects signaling events and cytokine production in human monocytes. J Leukoc Biol 2000, 67: 249-58.
43. New, D.C., Wong, Y.H. CC chemokine receptor-coupled signalling pathways. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2003, 35: 779-88.
44. Johnson, Z., Power, C.A., Weiss, C. et al. Chemokine inhibition - Why, when, where, which and how? Biochem Soc Trans 2004, 32: 366-77.
45. Miro, X., Casacuberta, J.M., Gutierrez-Lopez, M.D., de Landazuri, M.O., Puigdomenech, P. Phosphodiesterases 4D and 7A splice variants in the response of HUVEC cells to TNFα. Biochem Biophys Res Commun 2000, 274: 415-21.
46. Li, L., Yee, C., Beavo, J.A. CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science 1999, 283: 848-51.
47. + T-lymphocytes: Role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 1996, 118: 1945-58.
48. Smith, S.J., Brookes-Fazakerley, S., Donnelly, L.E., Barnes, P.J., Barnette, M.S., Giembycz, M.A. Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol Physiol 2003, 284: L279-89.
49. Gardner, C., Robas, N., Cawkill, D., Fidock, M. Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun 2000, 272: 186-92.
50. Sasaki, T., Kotera, J., Omori, K. Transcriptional activation of phosphodiesterase 7B1 by dopamine D1 receptor stimulation through the cyclic AMP/cyclic AMP-dependent protein kinase/cyclic AMP-response element binding protein pathway in primary striatal neurons. J Neurochem 2004, 89: 474-83.
51. Barber, R., Baillie, G.S., Bergmann, R. et al. Differential expression of PDE4 cyclic AMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and non-smokers. Am J Physiol Lung Cell Mol Physiol 2004, 287: L332-43.
52. Miro, X., Perez-Torres, S., Palacios, J.M., Puigdomenech, P., Mengod, G. Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs. Synapse 2001, 40: 201-14.
53. Kuthe, A., Wiedenroth, A., Magert, H.J. et al. Expression of different phosphodiesterase genes in human cavernous smooth muscle. J Urol 2001, 165: 280-3.
54. Ahlstrom, M., Pekkinen, M., Huttunen, M., Lamberg-Allardt, C. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation. Cell Mol Biol Lett 2005, 10: 305-19.
55. Reyes-Irisarri, E., Perez-Torres, S., Mengod, G. Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neuroscience 2005, 132: 1173-85.
56. Nemoz, G., Zhang, R., Sette, C., Conti, M. Identification of cyclic AMP-phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells. FEBS Lett 1996, 384: 97-102.
57. + T cell hyperactivation and HIV type 1 replication. Proc Natl Acad Sci USA 2000, 97: 14620-5.
58. Richter, W., Hermsdorf, T., Kronbach, T., Dettmer, D. Refolding and purification of recombinant human PDE7A expressed in Escherichia coli as inclusion bodies. Protein Exp Purif 2002, 25: 138-48.
59. + T-lymphocytes. Mol Pharmacol 2004, 66: 1679-89.
60. Wang, P., Wu, P., Egan, R.W., Billah, M.M. Cloning, characterization, and tissue distribution of mouse phosphodiesterase 7A1. Biochem Biophys Res Commun 2000, 276: 1271-7.
61. Wang, H., Liu, Y., Chen, Y., Robinson, H., Ke, H. Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7. J Biol Chem 2005, 280: 30949-55.
62. Vergne, F., Bernardelli, P., Lorthiois, E. et al. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: Design, synthesis and structure-activity relationship studies. Bioorg Med Chem Lett 2004, 14: 4607-13.
63. Vergne, F., Bernardelli, P., Lorthiois, E. et al. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: Metabolism-directed optimization studies towards orally bioavailable derivatives. Bioorg Med Chem Lett 2004, 14: 4615-21.
64. Bernardelli, P., Lorthiois, E., Vergne, F. et al. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives. Bioorg Med Chem Lett 2004, 14: 4627-31.
65. Lorthiois, E., Bernardelli, P., Vergne, F. et al. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1. Bioorg Med Chem Lett 2004, 14: 4623-6.
66. Martinez, A., Castro, A., Gil, C. et al. Benzyl derivatives of 2,1,3-benzo- and benzothieno[3,2-a]thiadiazine 2,2-dioxides: First phosphodiesterase 7 inhibitors. J Med Chem 2000, 43: 683-9.
67. Castro, A., Abasolo, M.I., Gil, C., Segarra, V., Martinez, A. CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2-alpha]thiadiazine 2,2-dioxides: Clues for the design of phosphodiesterase 7 inhibitors. Eur J Med Chem 2001, 36: 333-8.
68. Aubart, K.M., Christensen, S.B., Leber, J.D. (SmithKline Beecham Corp.) Compounds and their use as PDE inhibitors. US 6617357.
69. Castro, A., Jerez, M.J., Gil, C., Martinez, A. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: Advances in the development of specific phosphodiesterase inhibitors. Med Res Rev 2005, 25: 229-44.
70. Haughan, A.F., Lowe, C., Buckley, G.M. et al. (Celltech Chiroscience, Ltd.) Sulphonamide derivatives. WO 0198274.
71. Lowe, C., Dyke, H., Haughan, A.F., Calvin, F.C.A., Morgan, T., Picken, C.L. (Darwin Discovery, Ltd.) Heterobiarylsulphonamides and their use as PDE7 inhibitors. WO 0174786.
72. Editorial 1. PDE7 Inhibitors. Exp Opin Ther Patents 2004, 12: 601-3.
73. Barnes, M.J., Cooper, N., Davenport, R.J. et al. Synthesis and structure-activity relationships of guanine analogues as phosphodiesterase 7 (PDE7) inhibitors. Bioorg Med Chem Lett 2001, 11: 1081-3.
74. Dyke, H., Haughan, A.F., Lowe, C. et al. (Darwin Discovery, Ltd.) 9-(1,2,3,4-Tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as PDE7 inhibitors. WO 0068230.
75. Pitts, W.J., Vaccaro, W., Huynh, T. et al. Identification of purine inhibitors of phosphodiesterase 7 (PDE7). Bioorg Med Chem Lett 2004, 14: 2955-8.
76. Kempson, J., Pitts, W.J., Barbosa, J. et al. Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): Synthesis and initial structure-activity relationships. Bioorg Med Chem Lett 2005, 15: 1829-33.
77. Vaccaro, W., Roberge, J.Y., Leftheris, K., Pitts, W.J., Barbosa, J. (Bristol-Myers Squibb Co.) Purine inhibitors of phosphodiesterase. WO 02102314.
78. Guo, J., Barbosa, J., Pitts, W.J., Carlsen, M., Quesnelle, C., Dodier, M. (Bristol-Myers Squibb Co.) Pyrimidine inhibitors of phosphodiesterase (PDE) 7. WO 02102313.
79. Kansy, M., Senner, F., Gubernator, K. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 1998, 41: 1007-10.
80. Vergne, F., Ducrot, P., Adrainjara, C., Bernardelli, P., Lorthiois, E. (Warner-Lambert Co.) New thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors. EP 1326853.
81. Pitts, W., Barbosa, J. (Bristol-Myers Squibb Co.) Quinazoline and pyrido[2,3-d]pyrimidine inhibitors of phosphodiesterase (PDE) 7. WO 02102315.
82. Bernardelli, P., Ducrot, P., Lorthiois, E., Vergne, F. (Warner-Lambert Co.) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors. WO 02074754.
83. Bundschuh, D.S., Kley, H.-P., Steinhilber, W. (Byk Gulden Lomberg Chemische Fabrik) (Dihydro)isoquinolines derivatives as phosphodiesterase inhibitors. WO 0240450.
84. Steinhilber, W. (Byk Gulden Lomberg Chemische Fabrik) Dihydroisoquinolines as novel phosphodiesterase inhibitors. WO 0240449.
85. Eggenweiler, H.-M., Rochus, J., Wolf, M., Gassen, M., Poschke, O. (Merck Patent GmbH) Imidazole derivatives as phosphodiesterase VII inhibitors. WO 0129049.
86. Eggenweiler, H.-M., Rochus, J., Wolf, M., Gassen, M., Poschke, O. (Merck Patent GmbH) Imidazole compounds used as phosphodiesterase inhibitors. WO 0136425.
87. Eggenweiler, H.-M., Jonas, R., Wolf, M., Gassen, M., Welge, T. (Merck Patent GmbH) Imidazole compounds used as phosphodiesterase VII inhibitors. WO 0136425.
88. Eggenweiler, H.-M., Ackerman, K.-A., Jonas, R., Wolf, M., Gassen, M., Welge, T. (Merck Patent GmbH) Imidazopyhdine derivatives as phosphodiesterase VII inhibitors. US 6613778.
89. Inoue, H., Murafuji, H., Hayashi, Y. (Daiichi Suntory Pharma Co., Ltd.) Imidazotriazinone derivatives as PDE7 (phosphodiesterase 7) inhibitors. WO 2004111053.
90. Inoue, H., Murafuji, H., Hayashi, Y. (Daiichi Suntory Pharma Co., Ltd.) Pyrazolopyrimidone derivatives having PDE7-inhibitory activity. EP 1454897.
91. Terricabras-Belart, E., Segarra-Matamoros, V.M., Alvarez-Builla Gomez, J., Vaquera Lopez, J.J., Minguez Ortega, J.M. (Almirall Prodesfarma SA) 4-Aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives as PDE7 inhibitors. WO 2004065391.
92. Vergne, F., Bernardelli, P., Lorthiois, E., Ducrot, P. (Bristol-Myers Squibb Co.) (4,2-Disubstituted-thiazol-5-yl)amine compounds as PDE7 inhibitors. WO 03082839.
93. Yang, G., McIntyre, K.W., Townsend, R.M. et al. Phosphodiesterase 7A-deficient mice have functional T cells. J Immunol 2003, 171: 6414-20.
94. Michaeli, T. (Albert Einstein College of Medicine of Yeshiva University) Transgenic animal having a disrupted PDE7A gene and used thereof. US 6740793.
95. Nakata, A., Ogawa, K., Sasaki, T. et al. Potential role of phosphodiesterase 7 in human T cell function: Comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol 2002, 128: 460-6.
96. Essayan, D.M., Kagey-Sobotka, A., Lichtenstein, L.M., Huang, S.K. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Pharmacol Exp Ther 1997, 282: 505-12.
97. Landells, L.J., Szilagy, C.M., Jones, N.A. et al. Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects. Br J Pharmacol 2001, 133: 722-9.
98. Staples, K.J., Bergmann, M., Tomita, K. et al. Adenosine 3′,5′-cyclic monophosphate (cAMP)-dependent inhibition of IL-5 from human T lymphocytes is not mediated by the cAMP-dependent protein kinase A. J Immunol 2001, 167: 2074-80.
99. Jimenez, J.L., Punzon, C., Navarro, J., Munoz-Fernandez, M.A., Fresno, M. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-κB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther 2001, 299: 753-9.
100. Averill, L.E., Stein, R.L., Kammer, G.M. Control of human T-lymphocyte interleukin-2 production by a cAMP-dependent pathway. Cell Immunol 1988, 115: 88-99.
101. Robicsek, S.A., Blanchard, D.K., Djeu, J.Y., Krzanowski, J.J., Szentivanyi, A., Poison, J.B. Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem Pharmacol 1991, 42: 869-77.
102. Stein, C.A. The experimental use of antisense oligonucleotides: A guide for the perplexed. J Clin Invest 2001, 108: 641-4.
103. Hatzelmann, A., Marx, D., Steinhilber, W. (Altana Pharma AG) Phthalazinone derivatives useful as PDE4/7 inhibitors. WO 02085906.
104. Pitts, W.J., Watson, A.J., Dodd, J.H. (Bristol-Myers Squibb Co.) Dual Inhibitors of PDE7 and PDE4. WO 02088079.
105. Ukita, T., Sugahara, M., Terakawa, Y. et al. Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: Synthesis and biological activities of a series of 1-pyridyl-naphthalene derivatives. J Med Chem 1999, 42: 1088-99.
106. Perez-Torres, S., Cortes, R., Tolnay, M., Probst, A., Palacios, J.M., Mengod, G. Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization. Exp Neurol 2003, 182: 322-34.
107. Miller, A.D. Central mechanisms of vomiting. Dig Dis Sci 1999, 44: 39S-43S.
108. Miller, A.D., Leslie, R.A. The area postrema and vomiting. Front Neuroendocrinol 1994, 15: 301-20.
109. Robichaud, A., Tattersall, F.D., Choudhury, I., Rodger, I.W. Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology 1999, 38: 289-97.